International Journal of Academic Health and Medical Research (IJAHMR)
ISSN: 2643-9824
Vol. 9 Issue 7 July - 2025, Pages: 82-85

Rare Breast Tumors: Clinical Characteristics, Diagnostic Challenges, And Therapeutic Strategies

Z.Benaboud , A.Khattabi, N.Douzi M. Bendahhou Idrissi, N. Mamouni, S Errarhay, C Bouchikhi, A. Banani Obstetrics gynecology department I University hospital Hassan II Fez

Abstract: *Rare breast tumors constitute a heterogeneous group of neoplasms that represent less than 1% of all breast malignancies. These include phyllodes tumors, angiosarcomas, metaplastic carcinomas, adenomyoepitheliomas, and primary lymphomas of the breast. Due to their low incidence, these tumors pose significant diagnostic and therapeutic challenges, often mimicking more common breast pathologies. This review presents updated evidence on epidemiology, clinical presentation, diagnosis, and treatment of rare breast tumors, advocating for multidisciplinary, individualized management.*

Keywords: rare breast tumors, phyllodes tumor, angiosarcoma, metaplastic carcinoma, breast lymphoma

1. INTRODUCTION

Breast cancer is the most common cancer among women globally [1]. While invasive ductal and lobular carcinomas dominate, rare breast tumors account for a small but important subset. Their rarity contributes to diagnostic dilemmas, treatment uncertainty, and a paucity of clinical guidelines [2–4].

This review aims to consolidate current knowledge on the types, diagnosis, and management of rare breast tumors, including updates from recent clinical studies and histopathological classifications.

2. CLASSIFICATION OF RARE BREAST TUMORS

Table 1. Classification of Rare Breast Tumors

Mesenchymal Tumors:	Phyllodes tumor, Angiosarcoma, Liposarcoma
Mixed Tumors	Metaplastic carcinoma
Myoepithelial Tumors:	Adenomyoepithelioma, Myoepithelial carcinoma
Lymphoid Tumors:	Primary breast lymphoma, Plasmacytoma
Other Epithelial Tumors:	Secretory carcinoma, Adenoid cystic carcinoma
Neuroendocrine Tumors	

These tumors vary in biological behavior and require careful histological and immunohistochemical assessment for classification [5].

3. PHYLLODES TUMORS

Phyllodes tumors are fibroepithelial lesions representing <1% of all breast neoplasms [6].

Clinical Presentation

Rapidly enlarging, firm, painless masses, often mistaken for fibroadenomas [7].

Histological Subtypes

- Benign
-Borderline
-Malignant

These are determined based on mitotic count, stromal cellularity, atypia, and margins [8].



Figure 1. Histopathological features of malignant phyllodes tumor (leaf-like stromal overgrowth, increased mitoses).

Treatment
Wide local excision with >1 cm margins is standard. Axillary dissection is unnecessary unless clinically indicated. Malignant cases may benefit from adjuvant radiotherapy [9].

4. ANGIOSARCOMA
Primary and secondary angiosarcomas account for <0.05% of breast cancers [10].
Etiology
- Primary: young women, sporadic
-Secondary: radiation-induced or chronic lymphedema (Stewart-Treves syndrome)
Diagnosis
Histology shows atypical vascular channels; CD31, CD34, ERG are positive on IHC [11].
Management
Mastectomy is standard. Chemotherapy (e.g., anthracyclines) is considered in high-grade or metastatic disease [12].

Feature	Primary	Secondary
Age	20-40	>50
Latency	None	6-10 years
Site	parenchyma	Skin subcutis
Etiology	Sporadic	Radiation/ lymphedema

Table 2. Primary vs Secondary Angiosarcoma

Characteristics

5. METAPLASTIC CARCINOMA
Metaplastic carcinoma is a rare, aggressive subtype of triple-negative breast cancer (TNBC), accounting for <1% of cases [13].
Histologic Patterns
-Squamous
-Spindle-cell
-Heterologous (chondroid, osseous)
Prognosis
Worse than typical TNBC; 5-year survival ~50% [14].
Treatmeny
-Surgery ± radiation

-Limited chemotherapy sensitivity
-Trials on PI3K/mTOR inhibitors ongoing [15]

6. ADENOMYOEPITHELIOMA AND MYOEPITHELIAL CARCINOMA

Epidemiology
Rare tumors arising from epithelial and myoepithelial cells [16].
Histology
Biphasic growth with S100, calponin, and SMA positivity [17].
Clinical Behavior
Usually benign, but malignant transformation can occur.
Treatment
Complete excision with negative margins; malignancies may require further therapy [18].

7. PRIMARY BREAST LYMPHOMA (PBL)

PBL is a non-epithelial breast malignancy, usually diffuse large B-cell lymphoma (DLBCL) [19]
Diagnosis
Requires imaging (PET-CT) and core biopsy with flow cytometry.
Management
-R-CHOP chemotherapy
-No role for surgery
-CNS prophylaxis in high-risk cases [20]

8. NEUROENDOCRINE TUMORS (NETS)

Rare tumors with neuroendocrine differentiation. Diagnosis confirmed by chromogranin and synaptophysin positivity [21].
Treatment
Surgical excision. Poorly differentiated NECs may require platinum-based chemotherapy [22].

9. DIAGNOSTIC CHALLENGES

Due to their rarity and overlapping features with common tumors:
-Imaging is often nonspecific
-Core biopsy may miss diagnostic features
-Immunohistochemistry is essential for accurate typing
Molecular testing (e.g., NTRK, PIK3CA) is increasingly used in selected cases [23].

10. TREATMENT OVERVIEW

Tumor type	Primary treatment	Adjuvant therapy	Prognosis
Phyllodes (benign)	Excision	None	Excellent
Phyllodes (malignant)	Excision +/- RT	Radiation	Moderate
Angiosarcoma	Mastectomy	Chemo+/- RT	Poor
Metaplastic carcinoma	Surgery	Chemo+/- RT	Poor
PBL	Chemotherapy	Immunotherapy	Good
NFTs	surgery	Chemo	variable

Table 3. Treatment Modalities by Tumor Type

11. PROGNOSIS

Prognosis depends on tumor type and grade. High-grade sarcomas and metaplastic carcinomas carry the worst outcomes. Five-year overall survival:
-Benign phyllodes: >90%
-Angiosarcoma: 30–50%
-Metaplastic carcinoma: 50%
-PBL: 70–80% with appropriate chemotherapy [24–26]

12. CONCLUSION

Rare breast tumors require high diagnostic suspicion, expert histopathological assessment, and multidisciplinary care. Given limited prospective data, individualized treatment plans and enrollment in clinical trials are encouraged. Future advances in molecular profiling may open new therapeutic avenues.

REFERENCES

1. Bray F, et al. CA Cancer J Clin. 2021;71(3):209–249.
2. Tan PH, Ellis I. Histopathology. 2022;80(5):802–815.
3. Lakhani SR, et al. WHO Classification of Tumours of the Breast. 5th ed. IARC; 2019.
4. Eusebi V, et al. Virchows Arch. 2019;475(5):573–586.
5. Brogi E, et al. Mod Pathol. 2021;34(Suppl 1):98–113.
6. Mangi AA, et al. Ann Surg Oncol. 2020;27(4):1130–1135.
7. Barth RJ Jr, et al. Ann Surg Oncol. 2018;25(4):1042–1048.
8. Tan BY, et al. Mod Pathol. 2019;32(10):1512–1533.
9. Mitus JW, et al. Breast J. 2020;26(4):744–749.
10. Rosen PP. Breast Pathology. 3rd ed. Lippincott Williams & Wilkins; 2021.
11. Manner J, et al. Mod Pathol. 2020;33(4):554–566.
12. Bhosale P, et al. Radiographics. 2019;39(4):964–979.
13. Rayson D, et al. Cancer. 2018;112(6):1340–1347.
14. Pezzi CM, et al. Am J Surg. 2020;220(2):393–398.
15. Lee HJ, et al. J Clin Oncol. 2021;39(15_suppl):e13079.
16. Ghofrani M, et al. Am J Surg Pathol. 2019;43(8):1055–1063.
17. Chen D, et al. Int J Surg Pathol. 2020;28(7):682–689.
18. Gwin K, et al. Breast J. 2021;27(1):64–71.
19. Domchek SM, et al. Ann Intern Med. 2022;176(1):28–36.
20. Ryan G, et al. Ann Oncol. 2020;31(2):231–238.
21. Sapino A, et al. Mod Pathol. 2019;32(5):658–673.
22. Kim YJ, et al. J Breast Cancer. 2018;21(2):130–137.
23. Chmielecki J, et al. Nat Genet. 2021;53(3):305–310.
24. Telli ML, et al. J Natl Compr Canc Netw. 2022;20(4):389–397.
25. Dent R, et al. Clin Breast Cancer. 2019;19(2):e308–e318.
26. Li X, et al. Hematol Oncol. 2021;39(4):585–591.